Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes.
OBJECTIVE
The current study was undertaken to evaluate the effects of topically applied bimatoprost, an ocular hypotensive lipid, on intraocular pressure (IOP) and pupil size (PS) in healthy cats.


METHODS
Nine European Shorthair cats free from clinically relevant ocular abnormalities were used in the study.


METHODS
Pretreatment baseline measurements of IOP and PS were obtained bilaterally at 8 am, 2 pm, and 8 pm for five consecutive days (days 1 to 5). Then the cats received one drop twice daily (10 am and 6 pm) of bimatoprost ophthalmic solution 0.03% (Lumigantrade mark, Allergan Inc., Irvine, CA USA), in one randomly selected eye and one drop of artificial tears in the fellow eye (control eye) for 5 days (days 6 to 10). Values for IOP and PS were obtained under the same conditions as in the pretreatment phase. The potential for ocular irritation following bimatoprost application was also evaluated.


RESULTS
During the pretreatment period, the mean IOP and mean PS were not significantly different between the eyes subsequently treated with bimatoprost and those subsequently determined as controls. During the treatment period, the mean IOP in bimatoprost-treated eyes was not significantly lower than in control eyes (14.2+/-2.3 vs. 14.5+/-2.8 mmHg). Mean IOP in control eyes was not significantly changed at any time during the study period. A marked reduction of PS was seen in all bimatoprost-treated eyes, but no other clinically relevant side effects were observed.


CONCLUSIONS
Twice daily topical applications of bimatoprost produced miosis but had no significant effect on IOP in healthy cats.
Regnier
Alain
A
Department of Clinical Sciences, National Veterinary School, 31076 Toulouse, France. a.regnier@envt.fr
Lemagne
Capucine
C
Ponchet
Alice
A
Cazalot
Guillaume
G
Concordet
Didier
D
Gelatt
Kirk N
KN
D000287:Administration, Topical; D000577:Amides; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000069580:Bimatoprost; D002371:Cat Diseases / Q000139:chemically induced*; D002415:Cats; D003008:Cloprostenol / Q000031:analogs & derivatives; D005260:Female; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D008055:Lipids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D015877:Miosis / Q000139:chemically induced / Q000662:veterinary*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects*
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost